High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.
Moby summary of Recursion Pharmaceuticals, Inc.'s Q2 2026 earnings call
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028. The
Recursion Pharmaceuticals, Inc. reported its Q2 2026 results, with revenue falling to US$7.67 million from US$19.22 million a year earlier, while its net loss narrowed to US$131.01 million and loss per share improved to US$0.25. Alongside these figures, the company highlighted progress on its AI-enabled drug discovery platform, including Genentech advancing a neuroscience target into joint early discovery and updates on REC-4881 Phase 2 data and the upcoming REC-7735 clinical trial. With...
Recursion Pharmaceuticals stock has had a difficult run over the past several years, and the current valuation checks lean toward the shares looking expensive rather than like a clear bargain. Over the last 5 years, Recursion Pharmaceuticals has declined about 87%, which puts a clear focus on whether the current share price is aligned with the business outlook. The upcoming August 5 earnings call and business update can help shape expectations around Recursion Pharmaceuticals' ability to...
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $2.97, representing a -2.62% change from its previous close.
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $3.01, denoting a +1.69% move from the preceding trading day.
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $2.89, denoting a -1.87% move from the preceding trading day.
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the previous trading day.
Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.
Your hard-earned money would be better spent elsewhere.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Invest In According to Billionaires. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company that is building an AI-native discovery platform to industrialize drug discovery. Although still in the clinical stage, the company generates much of its revenue from key partnerships and collaborations with […]
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.72, moving 3.13% from the previous trading session.
In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including the Russell 2000 Value Index, expanding its presence in key equity indices. This index inclusion comes as Recursion’s AI‑native drug discovery platform and recent clinical and data‑driven milestones increasingly draw interest from large investors and collaborators. We’ll now examine how this broader index inclusion, alongside Recursion’s AI‑driven discovery progress,...
Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its current checks still point to a stock that screens as expensive rather than clearly cheap. Over the past 5 years, Recursion Pharmaceuticals shareholders have seen the stock decline about 90%, which puts extra focus on whether recent optimism is supported by today’s valuation. Progress with the AI driven drug discovery platform and clinical data for REC-4881 can...
Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest founder's shopping list.
Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry partnerships.
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
These aren't for the faint of heart.
Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.
Recursion Pharmaceuticals is trying to prove that AI’s next big winner can also come from biotech, and not just from the tech sector.
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.
X-Energy Inc. (NASDAQ:XE) is one of the 10 Stocks Stealing the Spotlight from Wall Street Giants. X-Energy saw its share prices increase by 13.50 percent on Monday to end at $21.10 apiece, mirroring the broader market optimism and Cathie Wood’s increased exposure to its stock. Last week, Wood’s global asset management, ARK Invest, announced that […]
Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery platform, along with progress in key clinical assets REC-1245 and REC-4881 and related regulatory discussions. See our latest analysis for Recursion Pharmaceuticals. At a share price of US$3.15, Recursion’s 30 day share price return of 3.28% contrasts with a year to date share price decline of 25% and a 1 year total shareholder return decline of 35.98%. This suggests recent...
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.